Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients.

Author(s): De Matos LD, Gardenghi G, Rondon MU, Soufen HN, Tirone AP, Barretto AC, Brum PC, Middlekauff HR, Negrao CE

Affiliation(s): Heart Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil.

Publication date & source: 2004-12, J Card Fail., 10(6):496-502.

Publication type: Clinical Trial; Randomized Controlled Trial

BACKGROUND: The long-term effects of carvedilol on muscle sympathetic nerve activity (MSNA) and muscle blood flow at rest and exercise in patients with chronic heart failure (CHF) remain unknown. METHODS AND RESULTS: Twenty-six patients (New York Heart Association class II-III) were randomized to carvedilol or placebo. Blood pressure, heart rate, MSNA, and forearm vascular resistance (FVR) at rest and during isometric forearm exercise (10% and 30% maximal voluntary contraction) were assessed before and after 6 months. Seven patients did not complete the study. Paired data were obtained in 19 (carvedilol 12, placebo 7). Carvedilol significantly decreased MSNA levels and heart rate at rest (-13 +/- 2 versus 3 +/- 8 bursts/min, P = .0001 and -16 +/- 3 vs -4 +/- 6 bpm, P = .05, respectively) and peak exercise (30% = -20 +/- 5 versus -3 +/- 7 bursts/min, P = 0.05 and -19 +/- 4 versus -4 +/- 6 bpm, P = 0.03, respectively) when compared with placebo. Carvedilol did not change a magnitude of response of MSNA and heart rate during exercise (-10 +/- 3 versus -7 +/- 2 bursts/min, P = 0.7 and 11 +/- 3 versus 6 +/- 1, P = .6, respectively). FVR was unchanged by carvedilol. When MSNA was quantified by burst incidence, the strength of reduction in MSNA was attenuated but still greater than placebo. CONCLUSIONS: Carvedilol reduces MSNA in patients with CHF. Carvedilol does not reduce FVR at rest or during isometric exercise.